JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1677/joe.0.1610041

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (42)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klein, M
Right arrow Articles by Leclere, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, M
Right arrow Articles by Leclere, J
Journal of Endocrinology, Vol 161, Issue 1, 41-49
Copyright © 1999 by Society for Endocrinology


Articles

Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma

M Klein, E Picard, JM Vignaud, B Marie, L Bresler, B Toussaint, G Weryha, A Duprez, and J Leclere


Angiogenesis is implicated in several pathological conditions, such as inflammation and tumor growth. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a potent stimulator of endothelial cell proliferation in vitro and in vivo. The present work aimed to compare VEGF expression in human normal thyroid glands, thyroiditis tissue and thyroid carcinomas using immunohistochemistry and in situ hybridization (ISH). Both chronic lymphocytic thyroiditis and differentiated thyroid carcinomas were found to strongly express VEGF mRNA and encode larger amounts of VEGF than normal thyroid tissue as attested by a VEGF immunostaining score. In addition, tumor samples from patients with metastases showed a higher immunostaining score than their non-metastatic counterparts (P<0.05). Carcinomas with the greatest contents of VEGF mRNA and VEGF protein had the most intense mitogenic activity. Special focus on endothelial cells showed intense mitogenic activity in neoplastic tissues in contrast to the total quiescence of endothelial cells in non-tumoral tissues. An intense VEGF production by differentiated thyroid carcinoma, attested either by a higher immunostaining score or a strong VEGF mRNA expression using ISH, could be a promising marker of tumor aggressiveness and may also be useful as a predictor of metastatic potential.


This article has been cited by other articles:


Home page
JCOHome page
E. E.W. Cohen, L. S. Rosen, E. E. Vokes, M. S. Kies, A. A. Forastiere, F. P. Worden, M. A. Kane, E. Sherman, S. Kim, P. Bycott, et al.
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
J. Clin. Oncol., October 10, 2008; 26(29): 4708 - 4713.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Joao Bugalho, D. Madureira, C. Espadinha, A. Paula Font, and L. G Sobrinho
Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma
Eur. J. Endocrinol., August 1, 2008; 159(2): 167 - 169.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al.
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Randi, M. Ferraroni, R. Talamini, W. Garavello, S. Deandrea, A. Decarli, S. Franceschi, and C. La Vecchia
Glycemic index, glycemic load and thyroid cancer risk
Ann. Onc., February 1, 2008; 19(2): 380 - 383.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
P.-J. Hsiao, M.-Y. Lu, F.-Y. Chiang, S.-J. Shin, Y.-D. Tai, and S.-H. H. Juo
Vascular endothelial growth factor gene polymorphisms in thyroid cancer
J. Endocrinol., November 1, 2007; 195(2): 265 - 270.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, and H. Kardymowicz
The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter
Eur. J. Endocrinol., October 1, 2007; 157(4): 521 - 527.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N G. de la Torre, I Buley, J A H Wass, and H E Turner
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 931 - 944.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Hoffmann, L. C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, and A. Zielke
Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cells in Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6139 - 6145.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Ye, C. Feng, S. Wang, K. Z. Q. Wang, N. Huang, X. Liu, Y. Lin, and M. Li
sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma
Endocrinology, February 1, 2004; 145(2): 817 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades
Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Sorvillo, G. Mazziotti, A. Carbone, M. Piscopo, M. Rotondi, M. Cioffi, P. Musto, B. Biondi, S. Iorio, G. Amato, et al.
Recombinant Human Thyrotropin Reduces Serum Vascular Endothelial Growth Factor Levels in Patients Monitored for Thyroid Carcinoma Even in the Absence of Thyroid Tissue
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4818 - 4822.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A.-C. Gerard, C. Daumerie, C. Mestdagh, S. Gohy, C. de Burbure, S. Costagliola, F. Miot, M.-C. Nollevaux, J.-F. Denef, J. Rahier, et al.
Correlation between the Loss of Thyroglobulin Iodination and the Expression of Thyroid-Specific Proteins Involved in Iodine Metabolism in Thyroid Carcinomas
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4977 - 4983.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Ye, C. Feng, S. Wang, X. Liu, Y. Lin, and M. Li
Antiangiogenic and Antitumor Effects of Endostatin on Follicular Thyroid Carcinoma
Endocrinology, September 1, 2002; 143(9): 3522 - 3528.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. M. Tuttle, M. Fleisher, G. L. Francis, and R. J. Robbins
Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1737 - 1742.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Klein, J.-M. Vignaud, V. Hennequin, B. Toussaint, L. Bresler, F. Plénat, J. Leclère, A. Duprez, and G. Weryha
Increased Expression of the Vascular Endothelial Growth Factor Is a Pejorative Prognosis Marker in Papillary Thyroid Carcinoma
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 656 - 658.
[Abstract] [Full Text]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society for Endocrinology.